Sarah E. Baker

11560 University Avenue, T6G 1Z2
Edmonton, AB, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Response to "Re: O'Reilly et al. On CTV utilization in non-spine bone oligometastases treated with SABR".

Response to "Re: O'Reilly et al. On CTV utilization in non-spine bone oligometastases treated with SABR".

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: May 18, 2026

Five-year follow-up of the SABR-5 trial: primary toxicity analysis of stereotactic ablative radiotherapy for up to five oligometastases.

Five-year follow-up of the SABR-5 trial: primary toxicity analysis of stereotactic ablative radiotherapy for up to five oligometastases.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: February 21, 2026

Stereotactic Body Radiotherapy Without Systemic Therapy for Oligometastatic Cancer: A Systematic Review and Meta-Analysis.

Stereotactic Body Radiotherapy Without Systemic Therapy for Oligometastatic Cancer: A Systematic Review and Meta-Analysis.

Journal: JAMA network open

Published: February 03, 2026

Treatment With Stereotactic Ablative Radiation Therapy for Patients With up to 5 Oligometastatic Cancer Lesions: Long-Term Outcomes of the Nonrandomized Population-based Phase 2 SABR-5 Clinical Trial.

Treatment With Stereotactic Ablative Radiation Therapy for Patients With up to 5 Oligometastatic Cancer Lesions: Long-Term Outcomes of the Nonrandomized Population-based Phase 2 SABR-5 Clinical Trial.

Journal: International journal of radiation oncology, biology, physics

Published: October 24, 2025

Rethinking clinical trial endpoints for evaluating serially delivered 'strategic radiotherapy' in oligometastatic or oligoprogressive metastatic disease.

Rethinking clinical trial endpoints for evaluating serially delivered 'strategic radiotherapy' in oligometastatic or oligoprogressive metastatic disease.

Journal: Cancer letters

Published: August 19, 2025

Multinational validation of distant metastasis velocity as a post-progression prognostic score in patients with oligometastatic cancer treated with metastasis-directed stereotactic body radiotherapy.

Multinational validation of distant metastasis velocity as a post-progression prognostic score in patients with oligometastatic cancer treated with metastasis-directed stereotactic body radiotherapy.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 18, 2025

Impact of clinical target volume utilization on outcomes in patients with non-spine bone oligometastases treated with stereotactic ablative radiation therapy.

Impact of clinical target volume utilization on outcomes in patients with non-spine bone oligometastases treated with stereotactic ablative radiation therapy.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: January 27, 2025

The Impact of Ultracentral Tumor Location on Outcomes in Patients with Pulmonary Oligometastases: A Secondary Analysis of the Single-Arm Phase 2 SABR-5 Trial.

The Impact of Ultracentral Tumor Location on Outcomes in Patients with Pulmonary Oligometastases: A Secondary Analysis of the Single-Arm Phase 2 SABR-5 Trial.

Journal: International journal of radiation oncology, biology, physics

Published: November 18, 2024

Evaluating Toxicity and Interaction Outcomes of Systemic Therapy and Stereotactic Ablative Radiation Therapy for Oligometastatic Disease: A Secondary Analysis of the Phase 2 SABR-5 Trial.

Evaluating Toxicity and Interaction Outcomes of Systemic Therapy and Stereotactic Ablative Radiation Therapy for Oligometastatic Disease: A Secondary Analysis of the Phase 2 SABR-5 Trial.

Journal: International journal of radiation oncology, biology, physics

Published: October 16, 2024

Beyond lesion count: Emphasizing disease pace in oligometastatic management.

Beyond lesion count: Emphasizing disease pace in oligometastatic management.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: September 20, 2024

Effect of Treatment Delivery Schedule for Patients With Early-Stage Non-Small Cell Lung Cancer Treated With Stereotactic Ablative Radiation Therapy: A Population-Based Analysis.

Effect of Treatment Delivery Schedule for Patients With Early-Stage Non-Small Cell Lung Cancer Treated With Stereotactic Ablative Radiation Therapy: A Population-Based Analysis.

Journal: Practical radiation oncology

Published: April 16, 2024

Single vs. multiple fraction non-inferiority trial of stereotactic ablative radiotherapy for the comprehensive treatment of oligo-metastases/progression: SIMPLIFY-SABR-COMET.

Single vs. multiple fraction non-inferiority trial of stereotactic ablative radiotherapy for the comprehensive treatment of oligo-metastases/progression: SIMPLIFY-SABR-COMET.

Journal: BMC cancer

Published: December 18, 2023

Showing 1-12 of 36

Last Updated: 09/26/2026